Abstract
The Orphan Drug Act, by providing incentives to pharmaceutical firms to develop new drugs for rare diseases, has helped many patients in the United States. This paper reviews its progress from its passage in 1983 to date, including the designation of 643 orphan products and the marketing approval of 125 of these. The next goal is to achieve harmonization with the European Union and Japan.
Get full access to this article
View all access options for this article.